Afficher la couverture 'Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial | Borget, Isabelle' en grand format
/5

0 avis

Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial

Archive ouverte

Borget, Isabelle | Bonastre, Julia | Catargi, Bogdan | Deandreis, Désirée | Zerdoud, Slimane | Rusu, Daniela | Bardet, Stéphane | Leenhardt, Laurence | Bastié, Delphine | Schvartz, Claire | Vera, Pierre | Morel, Olivier | Benisvy, Daniele | Bournaud, Claire | Bonichon, Françoise | Kelly, Antony | Toubert, Marie-Elisabeth | Leboulleux, Sophie | Journeau, Florence | Benhamou, Ellen | Schlumberger, Martin

Edité par CCSD ; American Society of Clinical Oncology -

International audience. In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two thyroid-stimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] and recombinant human TSH [rhTSH]) and the two iodine-131 ((131)I) activities (1.1 or 3.7 GBq). The objectives of this article were to present health-related quality-of-life (HRQoL) results and a cost-effectiveness evaluation performed alongside this trial.

Consulter en ligne

Suggestions

Du même auteur

Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial

Archive ouverte | Schlumberger, Martin | CCSD

International audience

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial

Archive ouverte | Leboulleux, Sophie | CCSD

International audience. Background ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [...

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Archive ouverte | Deandreis, Désirée | CCSD

International audience. Purpose: This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223 in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) differentiate...

Chargement des enrichissements...